Chameleon BioSurfaces, which develops biotechnology for medical device companies, has raised up to £475,000 from an investment syndicate led by London Seed Capital.
Seed Capital, which runs the four Oxford Technology VCTs, has reduced the valuation of one of its major investments – highly regarded biotech group Avidex.
Swedish entrepreneur Rolf Nordström is poised to float AIM’s first Scandinavian counter, Swedish biotech concern Tri-Pep, to advance an anti-HIV therapy.
